GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bloomios Inc (OTCPK:BLMS) » Definitions » Debt-to-Equity

Bloomios (Bloomios) Debt-to-Equity : -0.78 (As of Sep. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Bloomios Debt-to-Equity?

Bloomios's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $24.31 Mil. Bloomios's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.27 Mil. Bloomios's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-31.47 Mil. Bloomios's debt to equity for the quarter that ended in Sep. 2023 was -0.78.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bloomios's Debt-to-Equity or its related term are showing as below:

BLMS' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.01   Med: -1.86   Max: -0.78
Current: -0.78

During the past 10 years, the highest Debt-to-Equity Ratio of Bloomios was -0.78. The lowest was -17.01. And the median was -1.86.

BLMS's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.3 vs BLMS: -0.78

Bloomios Debt-to-Equity Historical Data

The historical data trend for Bloomios's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomios Debt-to-Equity Chart

Bloomios Annual Data
Trend Jun02 Jun03 Jun04 Jan05 Jan06 Jan07 Jan19 Jan20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.54 N/A N/A -1.63 -17.01

Bloomios Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.11 -17.01 -6.17 -4.16 -0.78

Competitive Comparison of Bloomios's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bloomios's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bloomios's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bloomios's Debt-to-Equity falls into.



Bloomios Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bloomios's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Bloomios's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bloomios  (OTCPK:BLMS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Bloomios Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bloomios's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Bloomios (Bloomios) Business Description

Traded in Other Exchanges
N/A
Address
701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101
Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.
Executives
Douglas S Rohrer officer: Chief Business Officer 701 ANACAPA, SUITE C, SANTA BARBARA CA 93101
Emc2 Capital Llc 10 percent owner 201 W MONTECITO STREET, SANTA BARBARA CA 93101
Barrett Evans director, 10 percent owner, officer: Pres, Chief Strategy Officer
Aline Hayuta Elkayam 10 percent owner 104 CHELSEA PLACE, ORMOND BEACH FL 32174
Bibi Daprile 10 percent owner 12 WINDING CREEK WAY, ORMOND BEACH FL 32174
Agpl Acquisition, Inc 10 percent owner 201 W MONTECITO ST., SANTA BARBARA CA 93101
Mammoth Crest Capital Llc 10 percent owner 1712 PIONEER AVE, SUITE 558, CHEYENNE WY 82001
Michael Hill director, 10 percent owner, officer: Chief Executive Officer 201 WEST MONTECITO STREET, SANTA BARBARA CA 93101
Bryan Glass director, 10 percent owner, officer: President and Director 20 WEST PARK AVENUE, SUITE 207, LONG BEACH NY 11561
Douglas Boyd director, officer: Chairman of the Board 8101 TIARA COVE CIR, LAS VEGAS NV 89128
Peter A Hogendoorn director, officer: President & CEO 13288 AMBLE GREEN PLACE, SURREY A1 V4A 6P5
Harold C Moll director, 10 percent owner
Van Laare Derek R officer: Secretary 6119 GORDON AVENUE, BURNABY A1 V5E 3M2
Carlo Civelli other: former director/officer/owner 111 SOMERSET ROAD, TRIPLE ONE SOMERSET 06-06, SINGAPORE U0 238164
Logan Anderson director, officer: President & Treasurer 15 HILL CRESCENT, PEMBROKE BERMUDA D8 00000